What does DR. NATASJA VAN GASSE, Klinische Biologie do?

DR. NATASJA VAN GASSE, Klinische Biologie is a specialist medical practice in Beveren-Kruibeke-Zwijndrecht. Private Limited, started on 31 March 2010, 1 establishment.

What is the address of DR. NATASJA VAN GASSE, Klinische Biologie?

The registered office of DR. NATASJA VAN GASSE, Klinische Biologie is located at Reigerslaan 12, 9150 Beveren-Kruibeke-Zwijndrecht.

Is DR. NATASJA VAN GASSE, Klinische Biologie still active?

Yes. According to the CBE (19 September 2026) DR. NATASJA VAN GASSE, Klinische Biologie is active, legal situation “Normale toestand”, started on 31 March 2010.

Is DR. NATASJA VAN GASSE, Klinische Biologie registered on Peppol?

Yes, DR. NATASJA VAN GASSE, Klinische Biologie is registered on the Peppol network with ID 0208:0824517519.

What is the enterprise number of DR. NATASJA VAN GASSE, Klinische Biologie?

The enterprise number of DR. NATASJA VAN GASSE, Klinische Biologie is BE0824517519.

When was DR. NATASJA VAN GASSE, Klinische Biologie founded?

DR. NATASJA VAN GASSE, Klinische Biologie was founded on 31 March 2010.

Who are the directors of DR. NATASJA VAN GASSE, Klinische Biologie?

According to the 2025 annual accounts, the directors of DR. NATASJA VAN GASSE, Klinische Biologie are: Natasja Van Gasse.

Is DR. NATASJA VAN GASSE, Klinische Biologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 March 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. NATASJA VAN GASSE, Klinische Biologie make in 2025?

DR. NATASJA VAN GASSE, Klinische Biologie posted a profit after taxes of € 164,774 in financial year 2025.

What is the revenue of DR. NATASJA VAN GASSE, Klinische Biologie?

As a small company, DR. NATASJA VAN GASSE, Klinische Biologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 216,786.

DR. NATASJA VAN GASSE, Klinische Biologie (Private Limited)

Dossier DR. NATASJA VAN GASSE, Klinische Biologie, printed on 19 September 2026 from databakkes.be/en/0824517519/dr-natasja-van-gasse-klinische-biologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. NATASJA VAN GASSE, Klinische Biologie from Beveren-Kruibeke-Zwijndrecht, company number BE0824517519, closed financial year 2025 with a result of € 164,774 after tax. For that financial year DR. NATASJA VAN GASSE, Klinische Biologie recorded a gross margin of € 216,786 and equity of € 1.5 million. Compared with financial year 2024, the result moved from € 236,219 to € 164,774. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Healthy

€ 1.5 million

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 164,774

▼ 30% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 260,630

▼ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 192,689 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 55,336

▼ 31% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 27,002

▼ 26% vs 2024

€ 11,395 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 1,337

▼ 18% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 10,676

▼ 49% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 662,170 Gross margin 2022: € 662,170 First fiscal year in the series	€ 317,390 Gross margin 2023: € 317,390 ▼ 52% vs 2022 (€ 662,170) Unfavourable step	€ 320,353 Gross margin 2024: € 320,353 ▲ 1% vs 2023 (€ 317,390) Favourable step	€ 216,786 Gross margin 2025: € 216,786 ▼ 32% vs 2024 (€ 320,353) Unfavourable step	▼ 32%
Profit after taxes	€ 446,161 Profit after taxes 2022: € 446,161 First fiscal year in the series	€ 227,004 Profit after taxes 2023: € 227,004 ▼ 49% vs 2022 (€ 446,161) Unfavourable step	€ 236,219 Profit after taxes 2024: € 236,219 ▲ 4% vs 2023 (€ 227,004) Favourable step	€ 164,774 Profit after taxes 2025: € 164,774 ▼ 30% vs 2024 (€ 236,219) Unfavourable step	▼ 30%
Equity	€ 1,414,665 Equity 2022: € 1,414,665 First fiscal year in the series	€ 1,506,903 Equity 2023: € 1,506,903 ▲ 7% vs 2022 (€ 1,414,665) Favourable step	€ 1,483,783 Equity 2024: € 1,483,783 ▼ 2% vs 2023 (€ 1,506,903) Unfavourable step	€ 1,455,868 Equity 2025: € 1,455,868 ▼ 2% vs 2024 (€ 1,483,783) Unfavourable step	▼ 2%
Total debts	€ 161,535 Total debts 2022: € 161,535 First fiscal year in the series	€ 72,068 Total debts 2023: € 72,068 ▼ 55% vs 2022 (€ 161,535) Favourable step	€ 93,032 Total debts 2024: € 93,032 ▲ 29% vs 2023 (€ 72,068) Unfavourable step	€ 48,600 Total debts 2025: € 48,600 ▼ 48% vs 2024 (€ 93,032) Favourable step	▼ 48%
Cash	€ 575,274 Cash 2022: € 575,274 First fiscal year in the series	€ 278,319 Cash 2023: € 278,319 ▼ 52% vs 2022 (€ 575,274) Unfavourable step	€ 325,857 Cash 2024: € 325,857 ▲ 17% vs 2023 (€ 278,319) Favourable step	€ 260,630 Cash 2025: € 260,630 ▼ 20% vs 2024 (€ 325,857) Unfavourable step	▼ 20%
Retained profit	€ 1,402,265 Retained profit 2022: € 1,402,265 First fiscal year in the series	€ 1,488,353 Retained profit 2023: € 1,488,353 ▲ 6% vs 2022 (€ 1,402,265) Favourable step	€ 1,465,233 Retained profit 2024: € 1,465,233 ▼ 2% vs 2023 (€ 1,488,353) Unfavourable step	€ 1,437,318 Retained profit 2025: € 1,437,318 ▼ 2% vs 2024 (€ 1,465,233) Unfavourable step	▼ 2%
Dividend	€ 104,326 Dividend 2022: € 104,326 First fiscal year in the series	€ 140,916 Dividend 2023: € 140,916 ▲ 35% vs 2022 (€ 104,326) Unchanged	€ 259,340 Dividend 2024: € 259,340 ▲ 84% vs 2023 (€ 140,916) Unchanged	€ 192,689 Dividend 2025: € 192,689 ▼ 26% vs 2024 (€ 259,340) Unchanged	▼ 26%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 46,129 Bank debt 2023: € 46,129 Unchanged (€ 0) Unfavourable step	€ 36,645 Bank debt 2024: € 36,645 ▼ 21% vs 2023 (€ 46,129) Favourable step	€ 27,002 Bank debt 2025: € 27,002 ▼ 26% vs 2024 (€ 36,645) Favourable step	▼ 26%
Balance sheet total	€ 1,576,200 Balance sheet total 2022: € 1,576,200 First fiscal year in the series	€ 1,578,971 Balance sheet total 2023: € 1,578,971 Unchanged (€ 1,576,200) Unchanged	€ 1,576,815 Balance sheet total 2024: € 1,576,815 Unchanged (€ 1,578,971) Unchanged	€ 1,504,468 Balance sheet total 2025: € 1,504,468 ▼ 5% vs 2024 (€ 1,576,815) Unchanged	▼ 5%

Key figures of DR. NATASJA VAN GASSE, Klinische Biologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. NATASJA VAN GASSE, Klinische Biologie?

What happened at DR. NATASJA VAN GASSE, Klinische Biologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 164,774 (▼ 30% vs 2024). Source: NBB ↗
Mar 31, 2010 New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
Mar 31, 2010 Start of the company according to the CBE. KBO

In short

From € 446,161 profit in 2022 to € 164,774 profit in 2025.

Paid € 412,871 in corporate taxes since 2022.

Best year ever: 2022, with € 446,161 profit.

Paid out € 697,270 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. NATASJA VAN GASSE, Klinische Biologie? We notify you, reason included.

Follow DR. NATASJA VAN GASSE, Klinische Biologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit